The three-year durability data is a strong positive catalyst for a clinical-stage biotech. Monitor ESMO poster presentation (Oct 24) and KOL webinar (Oct 29) for additional detail. Partnership or licensing interest may increase given sustained monotherapy responses. Cash runway into H2 2027 reduces near-term dilution risk.
Price Chart
Executive Summary
Evaxion reported three-year follow-up data from its Phase 2 trial of personalized cancer vaccine EVX-01 in advanced melanoma, showing 89% neoantigen hit-rate, sustained T-cell responses, and no tumor progression during the third year in all patients who maintained prior clinical response. The data supports both EVX-01 as a promising monotherapy and the AI-Immunology platform's target selection capability, with a cash runway extending into H2 2027.
Key Facts
- 89% of vaccine neoantigens generated potent specific T-cell responses at three-year follow-up.
- All patients maintained clinical response observed at two-year follow-up with no tumor progression through third year on EVX-01 monotherapy.
- Two-year data showed 75% Objective Response Rate with 25% complete response; 92% of patients still responding at two years.
- 54% of patients had deepened response (stable disease/partial response to partial/complete response) after starting EVX-01.
- Tumor reduction observed in 15 of 16 enrolled patients.
- Cash runway extends well into second half of 2027.
- Data to be presented at ESMO 2026 on October 24, 2026; webinar with KOL on October 29, 2026.
Financial Impact
No financial figures provided; clinical data de-risks EVX-01 and AI platform, potentially increasing partnership/licensing value for a $33M market cap company.
Risk Factors
- Phase 2 trial is small (16 patients); results may not replicate in larger Phase 3.
- No revenue or near-term approval path; company remains dependent on capital markets or partnerships.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006788 |
| Document: f6k_102226.htm | 0001171843-26-006788 |
| Document: 0001171843-26-006788-index-headers.html | 0001171843-26-006788 |
| Document: 0001171843-26-006788-index.html | 0001171843-26-006788 |
| Document: 0001171843-26-006788.txt | 0001171843-26-006788 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $3.76 $3.08 | ▼ −18.09% | ▼ −18.80% | $3.04 (−19.15%) |
Oct 19, 2026 8d ago | 6-K | $3.33 $4.05 | ▲ +21.62% | ▲ +21.29% | $3.04 (−8.71%) |
Oct 2, 2026 25d ago | 6-K | $3.20 $3.15 | ▼ −1.56% | ▼ −2.24% | $3.04 (−5.00%) |
Oct 2, 2026 25d ago | Press Release | $3.20 $3.15 | ▼ −1.56% | ▼ −2.24% | $3.04 (−5.00%) |
Sep 14, 2026 6w ago | 6-K | $3.07 $3.04 | ▼ −0.98% | ▼ −0.52% | $3.04 (−0.98%) |
Sep 4, 2026 7w ago | 6-K | $3.12 $3.17 | ▼ −1.60% | ▼ −2.15% | $3.04 (+2.56%) |
Aug 20, 2026 9w ago | 6-K | $3.28 $3.31 | ▲ +0.91% | ▲ +0.51% | $3.04 (−7.32%) |
Aug 20, 2026 9w ago | Press Release | $3.28 $3.31 | ▲ +0.91% | ▲ +0.51% | $3.04 (−7.32%) |
Aug 17, 2026 10w ago | 6-K | $3.13 $3.15 | ▲ +0.64% | ▲ +1.31% | $3.04 (−2.88%) |
Aug 14, 2026 10w ago | 6-K | $3.34 $3.13 | ▼ −6.29% | ▼ −5.81% | $3.04 (−8.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers